BETHESDA, Md.--(BUSINESS WIRE)--REGENERX BIOPHARMACEUTICALS, INC. (AMEX:RGN) (www.regenerx.com) announced today that it has been cleared by the FDA to begin its first phase 2 clinical trial to test its drug candidate, Thymosin beta 4 (Tß4), for the treatment of diabetic patients undergoing vitrectomy surgery. This will be RegeneRx’s first phase 2 clinical trial outside of the dermal wound healing field and an expansion of its technology platform.
